Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23

Become a member
  1. OncologyPRO
  2. Meeting Resources
  3. ESMO Virtual Congress 2020

F. Hoffmann-La Roche - Reshaping treatment paradigms for GU cancer patients: Perspectives on PI3K/AKT inhibitors in mCRPC and immunotherapy in urothelial cancer

Welcome and introduction

Date

22 Sep 2020

Session

F. Hoffmann-La Roche - Reshaping treatment paradigms for GU cancer patients: Perspectives on PI3K/AKT inhibitors in mCRPC and immunotherapy in urothelial cancer

Presenters

Karim Fizazi

Authors

K. Fizazi

Author affiliations

  • Cancer Medicine Department, Institut Gustave Roussy, 94805 - Villejuif/FR

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Login

Resources from the same session

Live Q&A - 23 September 2020 - 09:30-10:30

Presenter: Karim Fizazi

Session: F. Hoffmann-La Roche - Reshaping treatment paradigms for GU cancer patients: Perspectives on PI3K/AKT inhibitors in mCRPC and immunotherapy in urothelial cancer

Resources:

Webcast

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings

  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.